Prime Highlights-
- The liquid biopsy technique could reduce dependence on invasive brain surgery by analysing tumour DNA in cerebrospinal fluid.
- Early findings show the method can accurately classify brain tumours even when only minimal genetic material is available.
Key Facts-
- Researchers tested a liquid biopsy method that analyses tumour DNA in cerebrospinal fluid.
The approach allows tumour classification without the need for surgical tissue removal. - Early findings showed strong accuracy in identifying different brain tumour types.
Further large-scale clinical trials are required before the technique can be widely adopted.
Background-
A new study has introduced a different way to diagnose and classify brain tumours, potentially cutting down the need for major surgical procedures.
According to the research, scientists tested a liquid biopsy technique that looks for small amounts of tumour DNA in cerebrospinal fluid. Rather than removing a piece of the tumour through surgery, doctors can study this genetic material to understand what type of tumour is present and how it behaves.
The results indicate that doctors may be able to determine tumour type with strong accuracy without putting patients through invasive operations, marking an important step toward safer diagnostic options.
Rather than depending on samples taken during an operation, the method studies specific biological markers found within the tumour’s genetic material to identify the exact type of growth.
Initial results show that the technique can accurately tell apart different kinds of brain tumours, even when only very small amounts of tumour DNA are present.
This advancement suggests a future where diagnosis could become safer, quicker, and more precise for patients.
The advance is notable because diagnosing brain tumours has long depended on surgery to remove a portion of the tumor for laboratory analysis. Such operations are complex and can pose serious risks, particularly for children and patients with already delicate health.
The technique provides valuable biological insights that could deliver more personalized treatment decisions.
By understanding specific tumour characteristics, clinicians may be able to select therapies more effectively and monitor patient response with greater precision.
While additional large-scale clinical validation is required before widespread adoption, specialists view the findings as a meaningful step forward in neuro-oncology.
If future studies support these findings, the method may lead to safer testing, more reliable results, and better overall care for people with brain cancer.
